title: Increased pulmonary FDG uptake in bleomycin-associated pneumonitis.
abstract: BACKGROUND
  Bleomycin is an antineoplastic agent that is mainly used in combination regimens. Dose-limiting toxicity is the bleomycin-induced pneumonitis (BIP) that can be diagnosed by clinical and radiological findings. The early diagnosis of BIP is often challenging.
  
  
  METHODS
  We report the occurrence of a diffuse pulmonary increase of FDG uptake in the FDG-PET scan in association with suspected BIP in a patient treated for relapsed seminoma. A retroperitoneal relapse was treated with a combination chemotherapy containing cisplatin, etoposide, and bleomycin. After 3 cycles of this regimen the patient developed mild clinical signs of early BIP. A following FDG-PET in order to evaluate treatment response showed a diffuse increased FDG uptake of the right lung. The subsequent HRCT revealed pathological findings consistent with BIP. After cessation of bleomycin and a systemic steroid trial a prompt normalization of the abnormal radiological and clinical findings occurred together with a disappearance of the increased pulmonary FDG uptake.
  
  
  CONCLUSIONS
  FDG-PET can be used for evaluation of residual disease in patients treated for advanced seminoma. In cases of otherwise unexplained increased pulmonary FDG uptake in patients under treatment with bleomycin an evaluation for early BIP as a possible cause of this finding is warranted.
authors.affiliation: Abteilung Onkologie/Hämatologie, Kantonspital St. Gallen, Switzerland. lukas.vonrohr@kssg.ch
authors.forename: Lukas
authors.initials: L
authors.lastname: von Rohr
authors.forename: Bernd
authors.initials: B
authors.lastname: Klaeser
authors.forename: Markus
authors.initials: M
authors.lastname: Joerger
authors.forename: Thomas
authors.initials: T
authors.lastname: Kluckert
authors.forename: Thomas
authors.initials: T
authors.lastname: Cerny
authors.forename: Silke
authors.initials: S
authors.lastname: Gillessen
mesh_terms: D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000633:toxicity*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use / Q000633:toxicity; D001761:Bleomycin / Q000008:administration & dosage / Q000633:toxicity*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D011014:Pneumonia / Q000139:chemically induced* / Q000000981:diagnostic imaging; D049268:Positron-Emission Tomography; D018239:Seminoma / Q000188:drug therapy* / Q000473:pathology; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013737:Testis / Q000473:pathology; D014057:Tomography, X-Ray Computed
chemical_list: D000903:Antibiotics, Antineoplastic; D019788:Fluorodeoxyglucose F18; D001761:Bleomycin